Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide

Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We repor...

Full description

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2018-02, Vol.29 (2), p.517-518
Main Authors: Htet, T. D., Eisman, J. A., Elder, G. J., Center, J. R.
Format: Article
Language:English
Subjects:
Aged
Autoimmune diseases
Bone Density Conservation Agents - adverse effects
Bone Density Conservation Agents - therapeutic use
Calcification
Calcification (ectopic)
Calcinosis - chemically induced
Calcinosis - diagnostic imaging
Case Report
Connective Tissue Diseases - chemically induced
Connective Tissue Diseases - diagnostic imaging
Disease Progression
Endocrinology
Humans
Hypercalcemia
Male
Medicine
Medicine & Public Health
Orthopedics
Osteoporosis
Osteoporosis - drug therapy
Parathyroid hormone
Rheumatology
Teriparatide - adverse effects
Teriparatide - therapeutic use
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-017-4330-7